Peter Riedell to Hematologic Neoplasms
This is a "connection" page, showing publications Peter Riedell has written about Hematologic Neoplasms.
Connection Strength
0.180
-
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
Score: 0.180
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.